Autopsy report · NCT00803179

Growth Hormone Therapy for Wasting in Cystic Fibrosis

“Poor enrollment, patients were lost to follow up”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 4 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

University of Massachusetts, Worcester

Sponsor type

University, hospital or other

Conditions

Cystic Fibrosis

Interventions

Nutropin AQ

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• Comparison Study of Wound Closure at Time of Cesarean Delivery: Dermabond Glue Versus Surgical Staples
  “Poor enrollment, much data was missing as patients were lost to follow up” (90% match in meaning)
• Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis
  “Lost too many patients to follow up, unable to enroll enough patients” (83% match in meaning)
• Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-economic Comparison of Daptomycin vs. Vancomycin Based Regimens
  “Lack of patient enrollment” (80% match in meaning)
• Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract Surgery
  “Inadequate patient enrollment” (78% match in meaning)
• Short Forearm Casting Versus Below-elbow Splinting for Acute Immobilization of Distal Radius Fractures
  “lack of consistent enrollment, follow up and results” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.